Chinese preparation Xuesaitong promotes the mobilization of bone marrow mesenchymal stem cells in rats with cerebral infarction

After cerebral ischemia, bone marrow mesenchymal stem cells are mobilized and travel from the bone marrow through peripheral circulation to the focal point of ischemia to initiate tissue regeneration. However, the number of bone marrow mesenchymal stem cells mobilized into peripheral circulation is not enough to exert therapeutic effects, and the method by which blood circulation is promoted to remove blood stasis influences stem cell homing. The main ingredient of Xuesaitong capsules is Panax notoginseng saponins, and Xuesaitong is one of the main drugs used for promoting blood circulation and removing blood stasis. We established rat models of cerebral infarction by occlusion of the middle cerebral artery and then intragastrically administered Xuesaitong capsules（20, 40 and 60 mg/kg per day） for 28 successive days. Enzyme-linked immunosorbent assay showed that in rats with cerebral infarction, middle- and high-dose Xuesaitong significantly increased the level of stem cell factors and the number of CD117-positive cells in plasma and bone marrow and significantly decreased the number of CD54-and CD106-positive cells in plasma and bone marrow. The effect of low-dose Xuesaitong on these factors was not obvious. These findings demonstrate that middle- and high-dose Xuesaitong and hence Panax notoginseng saponins promote and increase the level and mobilization of bone marrow mesenchymal stem cells in peripheral blood.

Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction

Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group (n=96) and the treated group (n=108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group ( 66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.

Clinical Observation of the Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Post-hepatitis Fibrosis

Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (大黄NFDA1虫丸) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower ( P <0.01) than those before treatment. The differences between the two groups were insignificant ( P >0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.

Study of Interference Treatment by Xuesaitong (血塞通) Soft Capsuleon Patients of Nephrosis Syndrome with Qi Deficiency and Blood Stasisduring Dose Reducing Stage of Corticosteroid

Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods: Seventy-one NS patients applying prednisone and initiating dose reducing stage were randomized into trial group and control group. On the basis of conventional prednisone dose reduction of both groups, the trial group was given additionally XST, and the treatment course ended with the reduction to maintenance dose. In the course of observation, those who did not comply with the criteria of observation were excluded. Before and after the dose reduction, TCM syndrome scoring, 24 hrs urinary protein amount, blood β2-microglobulin (β2-MG), urinary β2-MG, blood fibrinogen (Fbg), plasma prothrombin time (PT), blood lipid, etc. were observed. Results: The trial group of XST could obviously lower their urinary protein amount and blood lipid level (P<0.05 or P<0.01), markedly improve the blood coagulation parameters (P<0.01), improve the TCM syndrome and CS induced adverse reaction (P<0.05 or P<0.01), also obviously reduced the recurrence rate of NS (P<0.05). Conclusion: XST could obviously improve the clinical symptoms and renal impairment parameters in NS patients during CS dose reduction stage, improve the CS induced adverse reaction and prevent the recurrence of NS.

Role of Xuesaitong in Amelioration of Neural Function and Alteration of Bax Expression in Rats with Brain Trauma

Traumatic brain injury (TBI) is one of the most common diseases in clinical neurosurgery characterized with high incidence rate, mortality and many complications. Objectives: The purpose of this study is to explore the roles of Xuesaitong in the therapeutic effect of brain trauma and alteration of expression in Bax, a kind of promoting apoptosis factor. Methods: The rat traumatic brain injury models were established by using modified free falling body impact method. Thereafter, Xuesaitong was employed to be administered to TBI rats, and NSS Score Rating Scale was used to evaluate the effect of Xuesaitong. Moreover, real-time PCR was used to detect the Bax expression changes before and after the Xuesaitong administration. Results: Xuesaitong could accelerate the neurofunctional recovery of TBI rats, accompanied by NSS Scores significant decrease. Simultaneously, it also could inhibit the expression of Bax factor. Conclusions: Xusaitong could markedly ameliorate TBI restoration, in which it promotes the neurofunctional recovery, and at the same time it inhibits the expression of Bax.

Meta-analysis of the effect of Xuesaitong combined with edaravone on hemorheological indexes in patients with acute cerebral infarction

Objective:To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction.Methods:Search CNKI,WanFang,VIP,SinoMed,PubMed,Cochrane Library and other databases,collect randomized controlled trials(RCTs)of Xuesaitong combined with edaravone in the treatment of acute cerebral infarction from the establishment of the database to November 2020,using RevMan 5.3 software Perform Meta analysis.Results:10 RCTs were included,with a total of 834 patients,417 in the experimental group and 417 in the control group.The results of Meta analysis showed that the experimental group was better than the control group in improving the whole plasma viscosity(MD=-0.73,95%CI[-0.83,-0.63],P<0.00001);in terms of improving the thrombosis coefficient,the test group is better than the control group(MD=-0.19,95%CI[-0.22,-0.15],P<0.00001);In terms of platelet aggregation rate,the test group was better than the control group(MD=-0.21,95%CI[-0.25,-0.17],P<0.00001).GRADE systematically evaluates whole plasma viscosity,thrombosis coefficient,and platelet aggregation rate,showing that the level of evidence is low or very low,and the strength of the recommendation is weak.Conclusion:Xuesaitong injection combined with edaravone injection has relatively satisfactory results in improving hemorheology indexes in patients with acute cerebral infarction,and there is no obvious safety problem.However,due to the small number of included studies and the total sample size,and the limitation of the quality of the included original studies,the results of this study need to be designed with strict,high-quality,large-sample,multi-center,and more internationally recognized clinical outcome indicators and efficacy experiments to verify,in order to obtain stronger evidence-based medicine.

Stability of Xuesaitong capsules in gastrointestinal lavage fluid

Objective:To obtain a formulation with high bioavailability through evaluation of the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats.We compared the stability of the Panax notoginsenoside R1 as well as the ginsenosides Rg1,Rb1,Re,and Rd in different formulations.Methods:Artificial stomach fluid(ASF)and artificial intestinal fluid(AIF)were prepared.Stability of three types of Xuesaitong capsules was examined for 4 h in stomachs and 24 h in intestines.Samples were analyzed at different times by high-performance liquid chromatography.Percent content of NGR1,GRg1,GRb1,GRe,and GRd at different times was calculated.Results:Hard capsules incubated in ASF disintegrated within 2e3 min,whereas soft capsules disintegrated within 7e8 min.Components in hard capsules were dissolved rapidly in water,with content of each compound reaching 90%in 5 min,and degradation of each compound reaching 30e50%after incubation for 240 min.Dissolution and degradation of each component in soft capsules with a water-soluble base tended to balance at 30 e90 min.Contents in soft capsules with a lipid-soluble base showed slow dissolution after ASF incubation for 120 min.Five saponins in identical types of capsules incubated in ASF had similar stability curves.Contents of hard capsules and soft capsules with a watersoluble base degraded rapidly within 30 min and reached a plateau when Xuesaitong capsules were incubated in AIF.

The study on the mechanism of Sodium aescinate combined with Xuesaitong for cerebral thrombosis treatment

Objective:To observe the mechanism of Sodium aescinate combined with Xuesaitong for cerebral thrombosis treatment and offer clinical help to cerebral thrombosis treatment. Methods:A total of 92 patients with cerebral thrombosis were selected and randomly divided into groups: the observation group (46 people) and the control group (46 people).The patient in the control group were treated with conventional therapy and the patients in the observation group were treated with Sodium aescinate combined with Xuesaitong on the basis of conventional therapy. Inflammatory factors (IL-6, IL-10, TNF-α and CRP), Nerve cell factor (NSE, NGF and NTF) and blood rheology indexes (Fg, BVH, BVL and PV) were detected and analyzed before and after treatment.Results:The comparison of inflammatory factors, Nerve cell factor and blood rheology indexes in the two groups before treatment were not statistically significant. Inflammatory factors (IL-6, TNF-α and CRP), Nerve cell factor (NSE) and blood rheology indexes (Fg, BVH, BVL and PV) in both groups after treatment significantly decreased compared with that before treatment. Inflammatory factors (IL-10), Nerve cell factor (GF and NTF) in both groups after treatment significantly increased compared with that before treatment. The changes were statistically significant. Inflammatory factors (IL-6, TNF-α and CRP), Nerve cell factor (NSE) and blood rheology indexes (Fg, BVH, BVL and PV) in observation group after treatment decreased more significantly than that in control group, and inflammatory factors (IL-10), Nerve cell factor (GF and NTF) increased more significantly than that in control group. The difference between two groups was considered statistically significant.Conclusion:Sodium aescinate combined with Xuesaitong could inhibit the inflammatory reaction, improve the blood flow condition and promote rehabilitation in patients with cerebral thrombosis. So it has a very important clinical significance of the treatment to cerebral hemorrhage.

Meta analysis of Xuesaitong injection in the treatment of angina pectoris of coronary heart disease

Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized controlled trial of Xuesaitong Injection in the treatment of angina pectoris of coronary heart disease from the beginning of the establishment of the database to January 2020.29 cases were finally included in the study through layer by layer selection.The total sample size was 2560 cases,including 1307 cases in the experimental group and 1253 cases in the control group.The data collected were meta analyzed by Revman 5.3 software.Results:on the basis of routine western medicine treatment,Xuesaitong injection was added in the clinical comprehensive effective rate([RR=1.31;95%CI(1.25,1.39)]),angina symptom improvement rate([RR=1.16;95%CI(1.07,1.26)]),ECG improvement rate([RR=1.25;95%CI(1.14,1.38)]),angina attack times([RR=-2.49;95%CI(-3.27,-1.70)]);fibrinogen([MD=-0.61;95%CI(-0.77,-0.45)]),plasma(specific)viscosity([MD=-0.19;95%CI(-0.22,-0.16)]),hematocrit([MD=-0.04;95%CI(-0.05,-0.03)])and other aspects were superior to the conventional treatment of Western medicine,the difference was statistically significant.Safety aspect:the reported adverse reactions were mild and tolerable events such as headache,dizziness,flush,etc.,no serious adverse events,and no separation from the report was found.Conclusion:on the basis of conventional western medicine,Xuesaitong injection can effectively improve the clinical efficacy,and has a high safety.However,due to the low quality of the included study and the small sample size,there is a potential bias in the study;therefore,the application and promotion of the research conclusions need to be cautious,and need to be further verified by more large sample,multicenter,double-blind clinical randomized controlled trials.

Effect of Xuesaitong Combined with Autologous Platelet-rich Gel on Blood Glucose,AT-III,TNF-αand 24-h Urinary Protein Level in Patients with Diabetic Foot

[Objectives]To investigate the clinical effect of different doses of Xuesaitong combined with autologous platelet-rich gel(APG)on patients with diabetic foot(DF).[Methods]90 patients with diabetic foot admitted to our hospital from February 2017 to February 2019 were enrolled in the study.According to the random number table method,the subjects were divided into study group A and B and control group C.Group A was given a low dose of Xuesaitong combined with APG,while group B was given high-dose Xuesaitong combined with APG and group C was treated only with APG.Patients in the three groups were observed and the changes of related indexes were detected.[Results]After treatment,with regard to the three groups,the fasting blood glucose,2-h postprandial blood glucose level,HbA1c,TNF-α,Hcy,blood urea nitrogen(BUN),creatinine(Cr)and 24-h urine protein levels were all decreased,yet AT-III level was increased,and granulation tissue coverage and thickness,wound clearance rate were increased,while the repair time of ulcer surface was significantly reduced.The above indexes were all significantly different(P<0.05).Compared with the control group C,the changes of the indexes in the study group A and B were the same as above,and the difference was significant(P<0.05).Compared with the study group A,the level of AT-III in group B was significantly increased(P<0.05),while TNF-α,Hcy,BUN,Cr and 24-h urine protein levels were significantly decreased(P<0.05).There was no significant difference in the other indexes between groups A and B(P>0.05).[Conclusions]Xuesaitong combined with APG could effectively reduce the blood sugar level of DF patients,improve the clinical indexes,promote wound healing,and the high-dose group had more significant advantages and was worthy of promotion.

Clinical Observation on Effect of Xuesaitong Injection (血塞通注射液) as Auxiliary Treatment of Severe Craniocerebral Injury

Objective To evaluate the effect of Xuesai-tong injection (XSTI, 血塞通注射液 , a preparation of Panax Notoginseng) as auxilliary treatment of severe craniocerebral injury. Methods Eighty-seven patients with severe craniocerebral injury were selected and randomly divided into the treated group (n=44) and the control group (n = 43), they were treated with conventional treatment, and XSTI was given additionally to the treated group. Intracranial pressure (ICP) and Glasgow coma score (GCS) of all patients were measuredafter 1 or 2-week treatment, and Glasgow outcome scale (GOS) of them was determined 3 months later. Then the therapeutic effect in the two groups were compared. Results After treatment, the ICP was lower, GCS higher and GOS better in the treated group than those in the control group significantly, all showing statistical significance (P<0.05). Conclusion XSTI has marked clinical therapeutic effect in treating patients with severe craniocerebral injury.Original article on CJITWM (Chin) 2004 ;23 (3): 213

Attenuation of Brain Inflammatory Response after Focal Cerebral Ischemia/Reperfusion with Xuesaitong Injection (血塞通注射液) in Rats

Objective： To investigate the neuro-protective effect of Xuesaitong Injection （血塞通注射液, XST） on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods： Focal cerebral ischemia/reperfusion models of male rats were induced by transient occlusion for 2 h of middle cerebral artery （MCA） which was followed by 24 h reperfusion. XST was administered through intraperitoneal injection of 25 mg/kg or 50 mg/kg at 4 h after the onset of ischemia. After reperfusion for 24 h, the neurological function score was evaluated, the brain edema was detected with dry-wet weight method, the myeloperoxidase （MPO） activity and the expression of intercellular adhesion molecule-1 （IOAM-l） of ischemic cerebral cortex and caudate putamen was determined by spectrophotometry and immunohistochemistry respectively. Results： XST not only lowered neurological function score at the dose of 50 mg/kg, but reduced brain edema and inhibited MPO activity and IOAM-1 expression as compared with the ischemia/reperfusion model group （P〈0.01）. Conclusion： XST has a definite effect on inhibiting the expression of IOAM-1 and neutrophil infiltration in rats with cerebral ischemia/reperfusion when treatment started at 4 h after ischemia onset, and also attenuates inflammation in the infarcted cerebral area.

血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者的影响

目的:探讨血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者的影响。方法:选取2022年1月至2023年6月在南京市中医院全科门诊治疗的160例后循环缺血性眩晕患者,随机将患者分为西药组和中西联合药物组,每组各纳入80例,西药组患者采用甲磺酸倍他司汀治疗,中西联合药物组采用血塞通联合甲磺酸倍他司汀治疗,两组患者均持续治疗2周。比较两组患者治疗前后临床症状采用眩晕评估评分量表(DARS)、眩晕障碍调查量表(DHI)和眩晕病临床证候评价量表评估、血液流变学包括血浆黏度(PV)、全血黏度(WVB)和全血纤维蛋白原(FIB),脑血流动力学包括左椎动脉(LVA)、右椎动脉(RVA)、基底动脉(BA)和阻力系数(RI)变化,并记录两组患者治疗期间的不良反应发生情况。结果:治疗后,中西联合药物组患者的DARS、DHI量表评分和眩晕病临床证候评价量表评分均较西药组低,差异有统计学意义(P<0.05);中西联合药物组PV、WVB和FIB水平均较西药组低,差异有统计学意义(P<0.05);中西联合药物组LVA、RVA和BA水平较西药组高,RI水平较西药组低,差异有统计学意义(P<0.05)。中西联合药物组寒战、心悸、皮疹、恶心呕吐不良反应率为10.00%,西药组为6.25%,差异无统计学意义(P>0.05)。结论:血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者可以改善患者临床疗效,降低患者的血压黏稠度,并有效调节患者脑血流动力循环。

基于Markov模型的血塞通软胶囊治疗 缺血性中风的成本效果分析

目的:基于中国卫生服务体系角度评价血塞通软胶囊对比安慰剂治疗缺血性中风患者的经济性。方法:基于血塞通软胶囊的Ⅲ期对照试验和已发表的文献数据构建markov模型,模拟患者终身的质量调整生命年(quality-adjusted life year,QALY)和增量成本效果比(Incremental cost-effectiveness ratio ICER),并进行单因素敏感性分析和概率敏感性分析检验模型的不确定性。结果:基础分析结果显示,与安慰剂组相比,血塞通软胶囊在获得0.32个QALY且节约医疗成本,具有绝对优势,单因素敏感性分析和概率敏感性分析验证了模型的稳健性。单因素敏感性分析显示对模型结果影响程度最大的4个因素分别是mRS3-5首次住院成本、mRS0-2首次住院成本、mRS0-2的状态效用值及贴现率;概率敏感性分析显示在我国的意愿支付值之下血塞通软胶囊具有经济性的概率为100%。结论:与安慰剂相比,血塞通软胶囊在提升QALY的同时降低了相应的成本,对治疗我国缺血性中风患者具有经济性。

Protective effects of combination of Xuesaitong and aspirin on cerebral ischemia and reperfusion injury in rats

Objective：To investigate the protective effects of the combination of Xuesaitong（XST）and aspirin on cerebral ischemia and reperfusion injury（CIRI）in rats,and further explore the underlying mechanisms.Methods：A total of 150 male Sprague-Dawley（SD）rats were randomly divided into five groups with 30rats in each group：sham group,middle cerebral artery occlusion/reperfusion（MCAO/R）model group,XST group,aspirin group,and XST＋aspirin group.Rats were pretreated with XST,aspirin,or XST＋aspirin for7 d.One hour after the last administration,a model of CIRI was induced by MCAO/R.Neurological deficits were assessed using Longa’s five-point scale.Cerebral edema was detected by the measurement of brain water content.The volume of cerebral infarction was determined by 2,3,5-triphenyltetrazolium chloride（TTC）staining.The activities of superoxide dismutase（SOD）,catalase（CAT）,and glutathione peroxidase（GSH-Px）,as well as levels of malonaldehyde（MDA）were detected by commercial kits.Enzyme-linked immunosorbent assay（ELISA）was used to determine the levels of interleukin-1（）,interleukin-4（IL-4）,interleukin-6（IL-6）,interleukin-10（IL-10）,tumor necrosis factor-alphamonocyte chemotactic protein 1（MCP-1）,and kynurenine in serum,cerebral cortex,and hippocampus of MCAO/R rats.The protein expression of nuclear factor erythroid 2-related factor（Nrf2）,heme oxygenase-1（HO-1）,I-kappa B alpha（IκBα）,and nuclear factor kappa B（B）/p65 in the cortex were analyzed by western blotting.Results：Treatment of XST,aspirin,and XST＋aspirin significantly alleviated the neurological deficits,cerebral edema,and cerebral infarct volume induced by MCAO/R.Treatment of XST,aspirin,and XST＋aspirin also reduced MDA,,MCP-1,and kynurenine levels,and increased SOD,CAT,GSH-Px,IL-4,and IL-10 levels in serum,cerebral cortex,and hippocampus of MCAO/R rats.Furthermore,treatment of XST,aspirin,and XST＋aspirin decreased the expression of nuclearB/p65 and increased the expression of IκBα,nuclear Nrf2,and HO-1.Importantly,the combination of XST and aspirin enhanced the protective effects of XST or aspirin treatment alone on CIRI in rats.Conclusion：The combination of XST and aspirin significantly inhibited oxidative stress and inflammation in serum,cerebral cortex,and hippocampus of MCAO/R rats.The combination of XST and aspirin exerted more protective effects than XST or aspirin treatment alone.The combination of XST and aspirin might provide the synergistic therapeutic effects on CIRI,and deserve further clinical investigation.

血塞通片体外溶出行为研究

目的 建立血塞通片溶出度检验方法,测定血塞通片中三七皂苷R_(1)、人参皂苷Rg_(1)、人参皂苷Re、人参皂苷Rb_(1)和人参皂苷Rd的整合溶出度。方法 以小杯法进行溶出度实验,采用高效液相色谱法(HPLC)测定5种指标成分的溶出量,采用质量分数权重系数法进行溶出度整合。绘制溶出曲线,采用f_(2)相似因子法比较各成分溶出曲线与整合溶出曲线的相似性,对整合溶出数据进行模型拟合,计算溶出参数T_(50)、T_(d)和T_(85)。结果 以水为溶出介质,转速50 r/min,60 min取样。5种指标成分溶出曲线与整合溶出度溶出曲线的f_(2)相似因子分别为64.5,61.6,79.8,60.0和68.2。溶出数据拟合模型以Weibull模型最优,溶出参数T_(50)、T_(d)和T_(85)分别为12.29 min、18.09 min和56.09 min。结论 建立的溶出度检查方法准确、可行,采用质量分数权重系数法整合溶出度能较好地表征血塞通片的体外溶出行为,可为血塞通片的质量一致性评价研究及质量控制提供技术借鉴。

血塞通滴丸联合达格列净治疗2型糖尿病合并慢性心力衰竭的效果及对PTS的影响

目的探究血塞通滴丸联合达格列净治疗2型糖尿病(T2DM)合并慢性心力衰竭(CHF)的效果及其对血糖代谢、心功能、血栓前状态(PTS)的影响。方法选取2022年7月—2023年7月收治的90例T2DM合并CHF,据随机数字表法分为研究组和对照组各45例。2组均予强心、利尿等抗心力衰竭治疗,在此基础上,对照组予达格列净治疗,研究组予血塞通滴丸联合达格列净治疗,治疗3个月后对比2组治疗效果、不良反应。比较2组治疗前后血糖指标、心功能指标、PTS指标、心力衰竭症状(Lee氏心力衰竭评分)、生活质量[明尼苏达心力衰竭生活质量量表(MLHFQ)评分]、血清Nexilin、可溶性致癌抑制因子2(sST2)水平。结果研究组总有效率为88.89%(40/45)明显高于对照组的71.11%(32/45)(P<0.05),而不良反应发生率比较无明显差异(P>0.05)。与治疗前比较,2组治疗1个月、3个月后外周血空腹血糖、糖化血红蛋白、餐后2 h血糖水平均降低(P<0.05)。与对照组比较,研究组治疗1个月、3个月后左心室射血分数升高,左心室舒张末期内径、左心室收缩末期内径及血清氨基末端脑钠肽前体水平降低(P<0.01);与对照组比较,研究组治疗1个月、3个月后血清组织型纤溶酶原激活物、纤溶酶原激活物抑制物-1水平升高,纤维蛋白原、血栓素B2、Nexilin、sST2水平降低(P<0.01);与对照组比较,研究组治疗1个月、3个月后Lee氏心力衰竭评分、MLHFQ评分降低(P<0.01)。结论在抗心力衰竭治疗基础上血塞通滴丸联合达格列净治疗T2DM合并CHF效果确切,可改善心功能、血糖代谢、PTS,并可提高生活质量,缓解心力衰竭病情进展,具一定安全性,可能与调节Nexilin、sST2表达有关。

血塞通联合倍他司汀对后循环缺血性眩晕患者椎-基底动脉血流动力学的影响

目的 探讨血塞通联合倍他司汀对后循环缺血性眩晕患者椎-基底动脉血流动力学的影响。方法 选取2021年1月至2022年12月西安唐城医院神经内科收治的80例后循环缺血性眩晕患者作为研究对象,根据用药方案不同将其分为常规组(40例,倍他司汀)和观察组(40例,血塞通联合倍他司汀)。比较两组的治疗效果。结果 观察组的治疗总有效率高于常规组,差异具有统计学意义(P<0.05)。治疗后,观察组的血浆黏度(PV)、全血黏度(WBV)、血小板聚集率(PAR)、红细胞比容(HCT)低于常规组(P<0.05)。治疗后,观察组椎-基底动脉最大血流速度(Vmax)、最小血流速度(Vmin)、平均血流量(Qmean)及降钙素基因相关肽(CGRP)水平高于常规组,外周阻力(RV)及内皮素-1(ET-1)水平低于常规组(P<0.05)。两组的不良反应总发生率无明显差异(P>0.05);随访1年,观察组的复发率显著低于常规组(P<0.05)。结论 血塞通联合倍他司汀可有效调节后循环缺血性眩晕患者血液流变学指标及椎-基底动脉的血流动力学指标,改善机体血液循环,取得安全、高效的理想效果。

中药汤剂联合血塞通注射液在脑梗死患者中的临床应用

目的分析脑梗死患者实施补阳还五汤+血塞通注射液治疗的效果。方法单纯随机选取2023年1月—2024年1月黔西市人民医院收治的脑梗死患者80例,经奇偶数分组法分为对照组、研究组,各40例。对照组行血塞通注射液治疗,研究组在对照组基础上加用补阳还五汤治疗,比较两组血脂指标、转归情况、有效率、不良反应。结果治疗后,研究组三酰甘油、总胆固醇均低于对照组,高密度脂蛋白胆固醇高于对照组,差异有统计学意义(P均<0.05)。治疗后,研究组美国国立卫生研究院卒中量表评分,改良Rankin量表分级低于对照组,差异有统计学意义(P均<0.05)。研究组治疗总有效率为97.50%,高于对照组的80.00%,差异有统计学意义(χ^(2)=6.135,P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论补阳还五汤与血塞通相结合后可提升疗效,不断降低血脂水平,减轻神经损伤程度,整体安全性高,能恢复脑梗死患者的自理能力。

血塞通注射液联合补阳还五汤治疗缺血性脑中风疗效观察

目的:研究缺血性脑中风联合采用血塞通注射液、补阳还五汤治疗的效果。方法:选取2021年11月—2023年11月河北省容城县中医医院脑病科接收的90例缺血性脑中风患者,以随机数字表法为依据,将其分为试验组(n=45)和对照组(n=45)。给予试验组患者补阳还五汤辅助血塞通注射液治疗,给予对照组患者血塞通注射液治疗。比较两组患者的血脂指标、神经功能和生活能力。结果:试验组患者接受治疗后除高密度脂蛋白胆固醇高于对照组患者外,其他血脂指标均低于对照组患者,差异有统计学意义(P<0.05);试验组患者神经功能评分为(8.70±2.44)分,低于对照组患者的(11.13±2.47)分,差异有统计学意义(t=4.695,P<0.05);试验组患者生活能力评分为(84.46±3.69)分,高于对照组患者的(79.20±7.91)分,差异有统计学意义(t=4.043,P<0.05)。结论:补阳还五汤辅助血塞通注射液治疗缺血性脑中风作用确切,能够有效地调节血脂水平,促进其神经功能改善及提高生活能力,值得推荐。